Lin Linus S, Lanza Thomas J, Castonguay Laurie A, Kamenecka Theodore, McCauley Ermenegilda, Van Riper Gail, Egger Linda A, Mumford Richard A, Tong Xinchun, MacCoss Malcolm, Schmidt John A, Hagmann William K
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.
Bioorg Med Chem Lett. 2004 May 3;14(9):2331-4. doi: 10.1016/j.bmcl.2004.01.098.
We have designed and synthesized a series of heterocyclic bioisosteres for an anilide based on molecular modeling. Excellent potency was retained in the benzoxazole and the benzimidazole derivatives, where a hydrogen bond acceptor is appropriately positioned to mimic the amide bond oxygen. The deletion of the hydrogen bond donor (N-H) led to improved lipophilicity and bioavailability. In the process, 9a was identified as a potent, specific, and bioavailable VLA-4 antagonist, while 9c was found to be a potent and bioavailable dual antagonist of VLA-4 and alpha(4)beta(7).
我们基于分子建模设计并合成了一系列用于酰苯胺的杂环生物电子等排体。苯并恶唑和苯并咪唑衍生物保留了优异的活性,其中氢键受体的位置适当,可模拟酰胺键氧。氢键供体(N-H)的缺失导致亲脂性和生物利用度提高。在此过程中,9a被鉴定为一种强效、特异性且具有生物利用度的VLA-4拮抗剂,而9c被发现是一种强效且具有生物利用度的VLA-4和α(4)β(7)双重拮抗剂。